Jonathan Goodman, MPhil

Oncology Editor

Jonathan has been the editor of Cancer Therapy Advisor since May 2016. He has a BA in philosophy and neuroscience from Emory University, as well as an MA and MPhil from the University of London, where he studied the philosophy of biology. He has previously worked on prostate cancer research at Memorial Sloan Kettering, and currently researches cultural evolution at CUNY. His work has appeared in Aeon Magazine, The Week, and Zygon: The Journal of Religion and Science.

Most Recent Articles by Jonathan Goodman, MPhil

Phase 2 Trial of Apatorsen for Metastatic Pancreatic Cancer Misses Primary Endpoint

Phase 2 Trial of Apatorsen for Metastatic Pancreatic Cancer Misses Primary Endpoint

By

Researchers evaluated whether adding apatorsen to a standard chemotherapy regimen would improve outcomes among patients with metastatic pancreatic cancer.

Tibetan Yoga May Improve Chemotherapy-related Fatigue

Tibetan Yoga May Improve Chemotherapy-related Fatigue

By

Researchers evaluated whether Tibetan yoga would improve fatigue and mitigate sleep disturbance more effectively than an active stretching program or a usual care control group.

Momelotinib vs Ruxolitinib for Myelofibrosis: Phase 3 Trial Yields Mixed Results

Momelotinib vs Ruxolitinib for Myelofibrosis: Phase 3 Trial Yields Mixed Results

By

Researchers compared the safety and efficacy of ruxolitinib vs momelotinib, a selective JAK1/2 inhibitor, among JAK inhibitor-naïve patients with myelofibrosis.

Novel Therapeutic Target in Chronic Lymphocytic Leukemia Cells Identified

Novel Therapeutic Target in Chronic Lymphocytic Leukemia Cells Identified

By

BCR signaling-stimulation was linked to NFATC1 activation in CLL cells; inhibiting NFAT led to CLL cell apoptosis.

Lifestyle Factors Associated With Colorectal Cancer Survival

Lifestyle Factors Associated With Colorectal Cancer Survival

By

For this follow-up analysis, several lifestyle factors including smoking status, exercise, and alcohol intake were reviewed to determine any relationship with CRC-specific survival.

More Articles by Jonathan Goodman, MPhil

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters